In this interview, Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beach, Florida, shares the results of the innovaTV 301 trial of tisotumab vedotin for patients with recurrent or metastatic cervical cance...
Oncology Data Advisor® · Tisotumab Vedotin for Metastatic Cervical Cancer: Results From ESMO 2023 With Brian Slomovitz, MD In this interview, Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beac...
Oncology Data Advisor® · Groundbreaking Results of Mirvetuximab Soravtansine for Ovarian Cancer With Kathleen Moore, MD Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. At the recent American Soci...
Oncology Data Advisor® · Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Noelle Cloven, a Gynecologic Oncologist at ...
The FDA has approved dostarlimab-gxly (Jemperli®, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for patients with mismatch repair–deficient (dMMR) or microsatellite instability–high (MSI-H) endometrial cance...
i3 Health has provided an educational activity that has challenged knowledge gaps experienced by the health care team regarding updates on immunotherapeutic strategies for recurrent or metastatic cervical cancer. This continuing medical education (CM...
The FDA has approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for treatment of mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen or who are not el...
